Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $45.00 at Wells Fargo & Company

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target reduced by equities researchers at Wells Fargo & Company from $47.00 to $45.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 77.80% from the company’s current price.

Other equities analysts have also issued reports about the stock. Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Cantor Fitzgerald raised their price target on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the stock an “overweight” rating in a report on Thursday, May 21st. Wedbush lowered their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Barclays dropped their target price on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Finally, Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $57.82.

Ultragenyx Pharmaceutical Trading Down 1.9%

Shares of RARE traded down $0.50 during midday trading on Wednesday, reaching $25.31. 1,030,734 shares of the stock were exchanged, compared to its average volume of 2,219,865. Ultragenyx Pharmaceutical has a 52 week low of $18.29 and a 52 week high of $39.89. The company’s 50 day moving average is $27.77 and its two-hundred day moving average is $24.76. The company has a market capitalization of $2.49 billion, a P/E ratio of -4.14 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The business had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. During the same quarter in the previous year, the business posted ($1.17) EPS. The company’s quarterly revenue was up 28.5% compared to the same quarter last year. On average, sell-side analysts expect that Ultragenyx Pharmaceutical will post -4.53 EPS for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 4,653 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $23.77, for a total transaction of $110,601.81. Following the transaction, the chief financial officer directly owned 105,689 shares of the company’s stock, valued at $2,512,227.53. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the sale, the executive vice president directly owned 94,462 shares of the company’s stock, valued at $2,325,654.44. This represents a 1.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 14,292 shares of company stock valued at $351,644. Corporate insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently bought and sold shares of the company. Parallel Advisors LLC lifted its position in shares of Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 1,440 shares in the last quarter. Leonteq Securities AG raised its stake in Ultragenyx Pharmaceutical by 288.5% in the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,333 shares during the last quarter. Versant Capital Management Inc lifted its holdings in Ultragenyx Pharmaceutical by 662.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,001 shares in the last quarter. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth $39,000. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 573.0% during the first quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 1,845 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reported a second-quarter loss of $0.90 per share, beating the consensus estimate for a $1.22 loss and improving from a $1.17 loss in the year-ago quarter. Revenue rose 28.5% year over year to $214 million, exceeding analysts’ $183.08 million estimate. Ultragenyx Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: Product performance was led by Crysvita revenue of $156 million and Dojolvi revenue of $27 million, supporting the company’s revenue growth. Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: Management reaffirmed 2026 revenue guidance of $730 million to $760 million and expects combined research and development and selling, general and administrative expenses to be flat to slightly lower than in 2025. Ultragenyx remains on track for profitability in 2027. Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: Investors have multiple second-half catalysts to watch, including two FDA PDUFA decisions and pivotal Phase 3 Aspire data for GTX-102 in Angelman syndrome. Ultragenyx Q2 2026 Earnings Call Transcript
• Negative Sentiment: Guggenheim lowered its price target from $43 to $35, although it maintained a Buy rating. The revised target still implies meaningful potential upside but signals more cautious valuation expectations. Guggenheim Price Target Update

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.